The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the treatment of obesity. Medications such as semaglutide (Wegovy), tirzepatide (Zepbound and Mounjaro), and liraglutide (Saxenda) have demonstrated an ability to produce significant weight loss in adults, making them some of the most consequential pharmaceutical developments in obesity medicine in decades. Increasingly, however, these medications are being prescribed to children and adolescents.
That expansion raises important questions. How strong is the long-term safety evidence in developing children? What are the potential consequences of altering appetite, digestion, body composition, and other physiological systems during childhood? And are medications being used to manage childhood obesity without adequately addressing the environmental and lifestyle factors contributing to it?
These questions deserve careful consideration as GLP-1 medications become a larger part of pediatric medicine.
In January 2023, the American Academy of Pediatrics published its Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. The recommendations represented a significant shift toward more intensive treatment of childhood obesity. The guideline supported consideration of pharmacotherapy in pediatric patients, including off-label treatment in some younger children, while also recommending evaluation for bariatric surgery for certain adolescents beginning at age 13.
Its release also came shortly after the FDA expanded approval of GLP-1 therapy for adolescents. Questions about potential conflicts of interest subsequently emerged.
According to a July 2025 BMJ investigation, GLP-1 drug manufacturers provided approximately $2 million in corporate sponsorship to the AAP between 2012 and 2024. Investigators also identified pharmaceutical-industry payments to 10 of the 27 members of the guideline-writing committee and 17 of 77 members of the organization’s national leadership.
Those financial relationships were reportedly not disclosed within the guideline or its accompanying technical report. Financial relationships do not by themselves demonstrate that a clinical recommendation is incorrect. They do, however, make transparency particularly important when recommendations could substantially increase medication use among children.
Since the release of the guidelines, prescribing has increased substantially. The figures include:
- A 38% increase in pediatric GLP-1 prescriptions during the first year following the guideline.
- A reported 700% increase for two particular GLP-1 medications.
- CDC data showing approximately a 300% increase in adolescent obesity-medication prescribing between 2020 and 2023.
- Semaglutide accounting for approximately 57% of adolescent obesity prescriptions, with the majority going to adolescents with severe obesity.
Although only a small percentage of adolescents with obesity currently receive these medications, the speed at which prescribing is increasing makes the quality and duration of pediatric safety evidence increasingly important.
GLP-1 receptors are not confined to the digestive system. They are found throughout the body, including in the cardiovascular system. Clinical trials have documented small increases in heart rate among patients taking GLP-1 receptor agonists.
There is also a more indirect cardiovascular concern. Nausea, vomiting, and diarrhea — well-recognized side effects of GLP-1 drugs — can cause dehydration and significant electrolyte abnormalities. This may be especially relevant in younger patients because pediatric prescribing information for Mounjaro reports a higher incidence of vomiting and abdominal pain among children than adults.
One of the less frequently discussed issues surrounding GLP-1 medications is body composition. When a patient loses weight, not all of the lost weight comes from body fat. This issue may carry different implications for children than for adults.
Childhood and adolescence are critical periods for building muscle and achieving peak bone mass. Researchers therefore need to understand whether prolonged pharmacologically-induced weight loss could affect skeletal development, muscle development, or long-term body composition.
There is also the issue of what happens when treatment ends. Loss of metabolically active lean tissue may be one of several factors contributing to weight regain after discontinuation, potentially making GLP-1 therapy a long-term treatment rather than a temporary intervention.
Perhaps the largest unanswered question involves the widespread distribution of GLP-1 receptors themselves. They are found in the brain, gastrointestinal tract, pancreas, heart, kidneys, lungs, thyroid, blood vessels, adipose tissue, immune cells, and bone. Researchers continue to investigate exactly what those receptors do in each organ system and how prolonged pharmacological activation may affect them.
Interest in GLP-1 medications as potential treatments for conditions such as neurodegenerative disease further demonstrates that their biological effects extend well beyond blood-sugar control and appetite regulation. That does not mean these additional effects are necessarily harmful. It means that the biological picture is more complex than appetite suppression alone — and that long-term pediatric research is especially important.
The duration and size of existing pediatric trials remain significant limitations. The pediatric approval of Mounjaro for type 2 diabetes relied on a 30-week study involving 99 pediatric participants. The longest pediatric weight-loss study referenced lasted 68 weeks. Neither timeframe can establish what may happen over many years of treatment with respect to growth, puberty, bone density, neurodevelopment, reproductive development, or other long-term outcomes.
The debate surrounding pediatric GLP-1 prescribing ultimately involves a larger question: What is driving childhood obesity in the first place?
Childhood obesity develops within a complicated environment involving food quality and availability, highly processed diets, refined carbohydrates, sedentary behavior, screen time, sleep, socioeconomic conditions, genetics, family habits, environmental exposures, and numerous other influences.
GLP-1 drugs may help reduce appetite and body weight, but they do not directly change that broader environment. That distinction matters.
For some children and adolescents with severe obesity or related metabolic disease, pharmacotherapy may ultimately prove to have an appropriate place alongside nutrition, physical activity, behavioral care, family support, and treatment of related medical conditions. But medication should not prevent clinicians, families, researchers, or policymakers from confronting the circumstances contributing to the rise in childhood obesity.
The central concern surrounding pediatric GLP-1 prescribing is not whether these medications can produce weight loss. The available evidence shows that they can. The larger question is whether enough is known about what prolonged treatment does to a developing body.
Children are not simply smaller adults. Their bones are developing. Their muscles are growing. Their endocrine systems are changing. Their brains and reproductive systems are maturing.
Let’s close with the words of the pediatrician and the author of the article we’ve used as one of the sources for this post, Dr. Michelle Perro:
Underlying this is a more fundamental question. Childhood obesity is a symptom of an altered food environment: ultra-processed foods, GMOs and their associated pesticides, refined carbohydrates, seed oils, endocrine-disrupting chemicals, and a sedentary, screen-based childhood. Pharmacologic appetite suppression addresses none of these. It intervenes downstream of the pathology while leaving the causes intact.
A therapeutic approach that treats the symptom while ignoring the etiology and that commits a child to indefinite medication without long-term safety data does not meet the standard of care to which pediatric patients are entitled.
Your responses and feedback are welcome!
Source: “GLP-1 Receptor Agonists in Pediatric Patients: An Evidence Review and Cautionary Analysis,” GMOScience.org, 8/27/26
Source: “Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics, 1/3/23
Image by Gustavo Fring/Pexels
FAQs and Media Requests: 
